Director Gregory Bailey Acquires 15,000 Shares of Biohaven Ltd (BHVN)

On May 13, 2024, Gregory Bailey, Director of Biohaven Ltd (BHVN, Financial), purchased 15,000 shares of the company. The transaction was filed with the SEC and can be viewed in detail through the SEC Filing.

Biohaven Ltd (BHVN, Financial) is a pharmaceutical company focused on the development and commercialization of treatments for neurological diseases, including rare disorders. The insider's recent purchase aligns with a pattern of buying activity over the past year, where the insider has acquired a total of 107,100 shares.

The shares were bought at a price of $34.19 each, valuing the transaction at approximately $513,000. Following this transaction, the market cap of Biohaven Ltd stands at approximately $3.49 billion.

Insider transactions provide insights into a company's internal perspective. Over the past year, Biohaven Ltd has experienced more insider buying than selling, with 12 insider buys and only 1 insider sell. This could indicate a positive outlook among the company's insiders about its future performance.


Investors often monitor insider transactions as they can provide valuable signals about the financial health and potential future performance of a company. For more detailed valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can visit the respective links.

The insider's recent purchase adds to the overall positive buying trend, potentially signaling confidence in the company's ongoing and future projects.

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.


I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.